



TM

SYSTEMATIX INSTITUTIONAL EQUITIES

Systematix

Institutional Equities

05 May 2024

Kotak Mahindra Bank

Strong treasury contribution boost 4QFY24 earnings.

Kotak Mahindra bank reported 4QFY24 PAT of Rs 41.3bn (+38% qoq, 18% yoy) which was higher than estimates due to (i) marginally improved NIMs (3bps benefit from interest on IT refund), (ii) higher other income on reversal of MTM losses and higher fee income, (iii) lower provisions due to reversal of ~80% AIF provision done in previous quarter and (iv) lower taxes from tax credits of Rs 2bn (5% of total tax).

Other key highlights were: (1) Advances growth of 4.6% qoq, 18% yoy was mainly led by 6-7% qoq growth in Commercial banking and SME. PL/BL/Cons. durables and credit cards growth was soft at 4% and was below bank's average growth. (2) Deposit growth (9% qoq, 24% yoy) was led by term deposit growth of 14.5% qoq. CASA ratio declined to 45.5% (-223bps qoq) as compared to peers witnessing an increase qoq. (3) C-D ratio reduced to 83.8% (-423bps qoq) and the bank expects it to be in the range of 86-87%. (4) Reported 4QFY24 NIM increased to 5.3% (+6bps qoq) with 3bps benefit from interest on IT refund. (5) Other income increased by 30% qoq due to reversal of MTM losses on SRs classified as NPI and seasonally higher distribution and syndication income which also benefitted from few large deals in infrastructure, real estate and NBFC financing space. (6) Opex is likely to increase in FY25 on the back of regulatory curbs and the bank guided for Rs 3.5-4.5bn of impact to PBT which reflects the net impact of curb on business operations related spends coupled with higher tech spends for strengthening core banking resilience amongst others. (7) GNPA declined to 1.4% (-34bps qoq) mainly due to higher write-offs in retail unsecured loans which were fully provided, mainly done to align with industry practice of writing off 180 dpd loans. (8) Basis RBI circular on 27-Mar'24, the bank released AIF provision of Rs 1.57bn (~80% of the provision made in Q3FY24). (9) RoA was 2.97% (2.5% ex Interest on IT refund, AIF provision reversal and tax credits).

We retain our BUY rating with a Mar'26 TP of Rs 1,815 (from Rs 2,095 earlier) valuing the standalone bank at 2.2x (earlier 2.5x) Mar'26 Adj BVPS for FY25-26E average RoA of 2.2%. We assign Rs 440 per share, post hold co discount, for its holding in the subsidiaries. We trim our loan growth estimates marginally and increase our opex estimates by ~6%.

Update on RBI's action on 24th April'24 regarding pause in onboarding new customers through bank's on-line and mobile banking channels and issuing fresh credit cards: The company reported that the order does not impact (i) servicing and cross-sell of products (excl. new credit cards) to existing customer base through all channels (ii) on-boarding new customers through other than online / mobile banking channels (iii) the bank will step up investments in IT (iv) redeploy resources to minimize the business impact. Overall, the management believes that these directions will not materially impact its overall business with the **management guiding for Rs 3.5-4.5bn hit to PBT (i.e ~2.5% of e.FY25 PBT) mainly stemming from higher tech spends partly offset by savings on customer acquisition costs due to ban on onboarding new customers digitally.**

Advances growth led by commercial and SME with softness in PL and credit cards: Advance growth (4.6% qoq, 18% yoy) was in-line with high teens growth guidance and was led by 6-7% qoq growth in Commercial banking and SME with strong growth in retail MFI (17% qoq) and CV/CE (9% qoq). Consumer banking growth of 5% was in-line with overall average growth while PL/BL/Cons. durables and credit cards growth

RESULT UPDATE

Sector: Banks **Rating: BUY**
CMP: Rs 1,550 **Target Price: Rs 1,815**

Stock Info

Sensex/Nifty	78,878/22,475
Bloomberg	KMB IN
Equity shares	1987mn
52-wk High/Low	Rs 2,063/1,544
Face value	Rs 5
M-Cap	Rs 3,075bn / USD 37bn
3-m Avg value	USD 150mn

Financial Snapshot (Rs bn)

Y/E March	FY24	FY25E	FY26E
NII	260	297	341
PPP	196	214	246
PAT	138	140	163
EPS (Rs)	69	70	82
EPS Gr. (%)	25.9	1.6	16.2
BV/Sh (Rs)	486	555	634
Adj. BV/Sh (Rs)	481	548	626

Ratios

NIM (%)	4.9	4.7	4.7
C/I ratio (%)	46.0	48.7	48.8
RoA (%)	2.5	2.2	2.2
RoE (%)	15.3	13.5	14.0
Payout (%)	2.9	2.9	2.9


Valuations

P/E (x)	16.0	15.8	13.6
P/BV (x)	2.3	2.0	1.8
P/Adj. BV (x)	2.3	2.0	1.8
Div. Yield (%)	0.1	0.1	0.2

Shareholding pattern (%)

	Sep'23	Dec'23	Mar'24
Promoter	26	26	26
-Pledged	-	-	-
FII	41	40	38
DII	20	21	23
Others	13	13	13

Stock Performance (1-year)



Manjith Nair

manjithnair@systematixgroup.in
+91 22 6704 8065

Pashmi Chheda

pashmichheda@systematixgroup.in
+91 22 6704 8063

Nirali Chheda

niralichheda@systematixgroup.in
+91 22 6704 8019

Investors are advised to refer disclosures made at the end of the research report.

of 4% was below bank's average growth. Corporate banking (net of IBPC) growth was flattish qoq. In FY24, the share of higher yielding consumer and commercial banking has increased by ~50bps each while that of lower yielding corporate book has declined by ~100bps. **The management remains confident of sustaining the current growth trend in customer assets despite RBI's supervisory actions on the back of cross-selling and deepening relationships with existing customer base.**

4Q NIMs supported by interest on IT refund and expected to remain stable going forward: Deposit growth (9% qoq, 24% yoy) was led by TD growth of 14.5% qoq, 43% yoy. CASA ratio declined to 45.5% (-223bps qoq) as compared to peers witnessing an increase qoq. TD- Sweep growth at 13% qoq was much lower as compared to 55-60% qoq growth seen in past 2 quarters. On reported basis, 4QFY24 NIM increased to 5.3% (+6bps qoq) with 3bps benefit from interest on IT refund. However, on calculated basis, NIM declined by -5bps qoq as (i) funding cost decreased by -16bps qoq, likely due to back-ended deposit growth and was more than offset by -18bps qoq decrease in average yields due to higher period end cash balances (ii) reduced leverage with C-D ratio reducing to 83.8% (-423bps qoq). The bank expects C-D ratio be in the range of 86-87% going forward. Despite the higher share of floating rate SA in total SA (23% vs 14% qoq), reported cost of SA balances declined to 4.13% (-19bps qoq), likely due to back-ended deposit growth. FY24 NIM at 5.32% was largely stable vs FY23 and in-line with guidance of ~5%. **The management does not foresee a need to materially increase TD rates as fallout of the RBI ban on onboarding customers via digital channels especially 811 as 70-75% of the customers acquired in the last 2 years has been via 811. It further guided for funding cost increase to be gradual in FY25 as the back-book has been largely repriced and it will also actively pursue refinance and infrastructure bond finance as means of incremental funding.**

Other income benefitted from one-offs; opex likely to increase on higher tech spends: Other income increased by 30% qoq due to (i) reversal of MTM losses in respect of SRs classified as NPI during Q3FY24 (ii) distribution and syndication income nearly doubling qoq on seasonality and also the bank benefitted from few large deals in infrastructure, real estate and NBFC financing space. As a result, CIR declined to 44.8% (-364bps qoq). **That said, opex is likely to increase in FY25 on the back of regulatory curbs and the bank guided for Rs 3.5-4.5bn of impact to PBT mainly stemming from higher tech spends.** Tech spends will continue to be about 10% of opex and the spends will be more towards increasing risk resiliency and capacity increase as opposed to adding new features/products in FY25.

Asset quality continues to remain largely stable despite higher write-offs: Gross / Net slippages increased to 1.43% / 0.6% vs (1.33% / 1.43% qoq). However, GNPA declined to 1.4% (-34bps qoq) and NNPA at 0.3% was stable qoq mainly due to higher write-offs (1.76% vs 0.16% qoq). **Retail unsecured loans which were fully provided, constituted 93% of the total write-offs. As per the management, this was mainly done to align with practice of writing off 180dpd unsecured loans and it remains comfortable with the asset quality of the unsecured book. Management further reiterated that despite credit cycles remaining benign, it will continue to maintain prudence in underwriting risk.** In 4Q, basis RBI circular of 27-Mar'24, the bank released AIF provision of Rs 1.57bn (~80% of the provision made in Q3FY24). Despite PCR declining to 76% (-464bps qoq), reported credit costs (incl. std provisions and excl. reversal of COVID & restructuring provisions) increased to 50bps vs 40bps qoq.

Valuation and recommendation: We retain our BUY rating with a Mar'26 TP of Rs 1,815 (from Rs 2,095 earlier) valuing the standalone bank at 2.2x (earlier 2.5x) Mar'26 Adj BVPS for FY25-26E average RoA of 2.2%. We assign Rs 440 per share (post Holdco discount of 20%) for its holding in the subsidiaries. We reduce our loan growth estimates and increase our opex estimates by 6%.

Key takeaways from 4QFY24 earnings call:

Balance sheet

- 79% (vs 81% in 3Q) of the investment book is in AFS and HFT with modified duration of 1.1yr
- In 4Q, CV disbursements 46% yoy, outpacing industry growth with the bank gaining market share.
- CE disbursements grew by 47% yoy and the company expects to retain the growth momentum.
- In FY24 tractor finance growth was flattish for the bank vs degrowth of 7.5% for the industry, thus indicating market share gains for the bank.
- Real estate book saw strong acquisitions in the latter half of the quarter.
- In mid -market the bank onboarded 2x the number of customers in FY24 vs FY23
- In MFI, Sonata acquisition was completed by end of Mar'24 with full impact in FY25. Post the acquisition, the bank's presence has increased to 16 states, 1400 BCs and customer count of 27 lakh women borrowers.
- Wholesale liabilities, which is current account largely grew even on account of higher share of flows and transaction banking in the corporate segment.

P&L

- The bank indicated of yield improvement in mortgages towards the end of the quarter.
- The bank continued to see pricing pressures in the SME and large corporate book
- The bank added 168 branches in FY24 (o/s 1948 branches) and 150 more to be added in FY25 as well.

Asset Quality

- Collection efficiencies in the CV segment remained stable.
- The bank reported initial signs of stress in tractor finance and MFI in monsoon deficient geographies. But yoy basis, collection efficiencies remained stable

Subsidiary performance

- Kotak securities: Overall market share increased to 11.8% in FY24 vs 9.6% in FY23
- Kotak Life: Embedded value growth of 21.8% yoy in FY24 and gross written premium growth of 16% yoy while individual APE growth was muted 4% yoy.
- Kotak Prime: AUM grew by 4.6% qoq. However, PAT degrew by 7%qoq on lower other income
- Kotak AMC: Total AUM increased by 5% qoq with equity AUM growth of 7.6% qoq.
- BSS Micro finance post FY24 PAT of Rs 3.83bn (+29% yoy)

Exhibit 1: Quarterly performance


(INR, mn)	4QFY24	4QFY23	YoY (%)	3QFY24	QoQ (%)
Interest income	1,23,071	98,209	25%	1,17,990	4.3%
Interest expenses	53,977	37,184	45%	52,455	2.9%
NII	69,094	61,026	13%	65,535	5.4%
Other income	29,783	21,860	36%	22,970	29.7%
Operating income	98,876	82,886	19%	88,505	11.7%
Operating expenses	44,261	36,415	22%	42,843	3.3%
- Staff expenses	18,264	14,545	26%	17,483	4.5%
PPOP	54,616	46,471	18%	45,662	19.6%
Provisions	2,637	1,476	79%	5,791	-54.5%
Profit before tax	51,978	44,995	16%	39,871	30.4%
Taxes	10,645	10,042	6%	9,821	8.4%
Profit after tax	41,333	34,953	18%	30,050	37.5%
Key Ratios (%)	4QFY24	4QFY23	YoY (bps)	3QFY24	QoQ (bps)
Net Advances growth (YoY, %)	17.6%	17.9%	-35 bp	15.7%	185 bp
Net Advances growth (QoQ, %)	4.6%	2.9%	165 bp	3.2%	134 bp
Deposit growth (YoY, %)	23.6%	16.5%	715 bp	18.6%	509 bp
Deposit growth (QoQ, %)	9.9%	5.3%	452 bp	1.9%	795 bp
CASA Ratio	45.5%	52.8%	-733 bp	47.7%	-223 bp
CD Ratio	83.8%	88.1%	-433 bp	88.0%	-423 bp
NIM (reported)	5.3%	5.8%	-47 bp	5.2%	6 bp
Cost to Income	44.8%	43.9%	83 bp	48.4%	-364 bp
Credit costs	0.5%	0.2%	25 bp	0.4%	11 bp
GNPA (%)	1.4%	1.8%	-39 bp	1.7%	-34 bp
NNPA (%)	0.3%	0.4%	-3 bp	0.3%	0 bp
PCR (%)	75.9%	79.3%	-340 bp	80.6%	-464 bp
CAR	21.8%	21.8%	0 bp	22.2%	-40 bp
Tier-I	20.7%	20.6%	10 bp	21.2%	-50 bp

Source: Company, Systematix Institutional Research


Exhibit 2: DuPont analysis

Du Pont (% of average assets)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24
Net interest income	5.1%	5.0%	4.8%	4.9%	4.8%
Other income	1.8%	2.1%	1.8%	1.7%	2.1%
Total income	6.9%	7.1%	6.6%	6.6%	6.9%
Operating expenses	3.1%	3.2%	3.1%	3.2%	3.1%
Employee expenses	1.2%	1.3%	1.3%	1.3%	1.3%
PPOP	3.9%	3.9%	3.5%	3.4%	3.8%
Provisions	0.1%	0.3%	0.3%	0.4%	0.2%
PBT	3.8%	3.7%	3.2%	3.0%	3.6%
PAT (RoAA)	2.9%	2.8%	2.4%	2.2%	2.9%
Leverage	5.86	5.90	5.93	5.93	6.06
ROE	17.2%	16.2%	14.5%	13.2%	17.4%


Source: Company, Systematix Institutional Research

Exhibit 3: Commercial and SME credit drive strong credit growth


Source: Company, Systematix Institutional Research

Exhibit 4: CASA ratio declined qoq


Source: Company, Systematix Institutional Research

Exhibit 5: NIM increased by 6bps qoq


Source: Company, Systematix Institutional Research

Exhibit 6: Opex to increase going forward due to higher tech spends


Source: Company, Systematix Institutional Research

Exhibit 7: Credit costs decreased due to AIF provisions reversal


Source: Company, Systematix Institutional Research

Exhibit 8: Return ratios remained strong. 4QFY24 RoA at 2.9%


Source: Company, Systematix Institutional Research

Exhibit 9: Asset quality largely stable.


Source: Company, Systematix Institutional Research

Exhibit 10: Unsecured retail was at 11.8% of portfolio

Source: Company, Systematix Institutional Research

Exhibit 11: 1-year forward P/ABV (x) trajectory

Source: Company, Systematix Institutional Research

Exhibit 12: 1-year forward P/ABV (x) near long term average

Source: Company, Systematix Institutional Research

FINANCIALS

Profit & Loss Statement

YE: Mar (Rs bn)	FY22	FY23	FY24	FY25E	FY26E
Interest Income	270	343	458	554	639
Interest Expenses	102	127	198	257	298
Net Interest Income	168	216	260	297	341
Change (%)	9.6	28.1	20.6	14.3	14.7
Commission, Ex. & Br. Inc.	42	54	67	83	99
Add: Other income	18	16	35	38	41
Net Income	228	286	363	417	481
Change (%)	12.1	25.6	26.7	15.1	15.2
Operating Expenses	108	138	167	203	235
Operating Profit	121	148	196	214	246
Change (%)	2.5	23.2	31.9	9.4	14.9
Provisions	7	5	16	28	29
PBT	114	144	180	187	217
Tax	28	35	42	47	54
Tax Rate (%)	24.5	24.0	23.5	25.0	25.0
PAT	86	109	138	140	163
Change (%)	23.1	27.6	26.0	1.6	16.2
Proposed Dividend	2	3	4	4	5

Source: Company, Systematix Institutional Research

Dupont

YE: Mar (%)	FY22	FY23	FY24	FY25E	FY26E
Interest Income	6.7	7.5	8.4	8.6	8.5
Interest Expended	2.5	2.8	3.6	4.0	4.0
Net Interest Income	4.1	4.7	4.8	4.6	4.5
Commission, Ex. & Br. Inc.	1.0	1.2	1.2	1.3	1.3
Other Fee Income	0.4	0.5	0.8	0.5	0.4
Net Operating Income	5.6	6.4	6.8	6.3	6.3
Profit on sale of investment	(0.0)	(0.2)	(0.1)	0.1	0.1
Net Income	5.6	6.2	6.7	6.4	6.4
Operating Expenses	2.6	3.0	3.1	3.1	3.1
Operating Income	3.0	3.2	3.6	3.3	3.3
Provisions	0.2	0.1	0.3	0.4	0.4
PBT	2.8	3.1	3.3	2.9	2.9
Tax	0.7	0.8	0.8	0.7	0.7
PAT	2.1	2.4	2.5	2.2	2.2
Leverage	6.0	5.9	6.1	6.3	6.4
RoE	12.7	14.1	15.3	13.5	13.7

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs bn)	FY22	FY23	FY24	FY25E	FY26E
Capital	10	10	10	10	10
Reserves & Surplus	710	820	956	1,092	1,251
Net Worth	720	830	967	1,103	1,261
Change (%)	13.9	15.3	16.5	14.1	14.3
Deposits	3,117	3,631	4,490	5,255	6,140
Change (%)	11.3	16.5	23.6	17.0	16.9
CASA Ratio (%)	60.7	52.8	45.5	43.5	41.5
Borrowings	279	254	304	335	369
Other Liabilities	179	183	243	255	268
Total Liabilities	4,294	4,899	6,004	6,947	8,038
Change (%)	12.0	14.1	22.6	15.7	15.7
Investments	1,006	1,214	1,554	1,911	2,198
Cash & Bank balance	429	325	528	490	559
Loans	2,713	3,199	3,761	4,381	5,108
Change (%)	21.3	17.9	17.6	16.5	16.6
Fixed Assets	16	19	22	24	28
Other Assets	130	141	139	140	145
Total Assets	4,294	4,899	6,004	6,947	8,038

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY22	FY23	FY24	FY25E	FY26E
Spreads Analysis (%)					
Yield on Advances	7.8	9.1	10.2	10.4	10.3
Yield on Earning Assets	6.9	7.7	8.7	8.8	8.7
Cost of Deposits	3.1	3.5	4.5	4.9	4.9
Cost of Funds	3.2	3.5	4.6	5.0	4.9
NIM	4.3	4.9	4.9	4.7	4.7
Profitability Ratios (%)					
Cost/Income	47.2	48.1	46.0	48.7	48.8
PPOP / Avg. assets	3.0	3.2	3.6	3.3	3.3
RoE	12.7	14.1	15.3	13.5	14.0
RoA	2.11	2.38	2.53	2.16	2.18
Asset Quality (%)					
GNPA (Rs bn)	65	58	53	73	88
NNPA (Rs bn)	17	12	13	18	22
GNPA	2.3	1.8	1.4	1.6	1.7
NNPA	0.6	0.4	0.3	0.4	0.4
PCR	73.2	79.3	75.9	75.1	75.1
Capitalisation (%)					
CAR	22.7	21.8	19.8	19.4	19.1
Tier I	21.7	20.8	19.5	19.1	18.8
Tier II	1.0	1.0	0.3	0.3	0.3
Average Leverage on Assets (x)	6.0	5.9	6.1	6.3	6.3
Valuations					
Book Value (Rs)	361	416	486	555	634
Adj. Book Value (Rs)	356	413	481	548	626
Price-BV (x)	3.1	2.7	2.3	2.0	1.8
Price-Adj. BV (x)	3.1	2.7	2.3	2.0	1.8
EPS (Rs)	43.2	55.1	69.3	70.5	81.9
EPS Growth (%)	22.9	27.5	25.9	1.6	16.2
Price-Earnings (x)	25.7	20.2	16.0	15.8	13.6
Dividend (Rs)	1	2	2	2	2
Dividend Yield (%)	0.1	0.1	0.1	0.1	0.2

Source: Company, Systematix Institutional Research

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
--------------------------	--------------------------	-------------------------	----------------------------------

Equity Research

Analysts	Industry Sectors	Desk-Phone	E-mail
Dhananjay Sinha	Co Head of Equities & Head of Research - Strategy & Economics	+91-22-6704 8095	dhananjaysinha@systematixgroup.in
Abhishek Mathur	FMCG	+91-22-6704 8059	abhishekmathur@systematixgroup.in
Ashish Poddar	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8039	ashishpoddar@systematixgroup.in
Himanshu Nayyar	Consumer Staples & Discretionary	+91-22-6704 8079	himanshunayyar@systematixgroup.in
Manjith Nair	Banking, Insurance	+91-22-6704 8065	manjithnair@systematixgroup.in
Pradeep Agrawal	NBFCs & Diversified Financials	+91-22-6704 8024	pradeepagrawal@systematixgroup.in
Pratik Tholiya	Specialty & Agro Chem, Fertilisers, Sugar, Textiles and Select Midcaps	+91-22-6704 8028	pratiktholiya@systematixgroup.in
Sameer Pardikar	IT & ITES	+91-22-6704 8041	sameerpardikar@systematixgroup.in
Santosh Yellapu	Capital Goods	+91-22-6704 8094	santoshiyellapu@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Sudeep Anand	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8085	sudeepanand@systematixgroup.in
Vishal Manchanda	Pharmaceuticals and Healthcare	+91-22-6704 8064	vishalmanchanda@systematixgroup.in
Chetan Mahadik	Consumer Staples & Discretionary	+91-22-6704 8091	chetanmahadik@systematixgroup.in
Deeksha Bhardwaj	Strategy & Economics	+91-22-6704 8017	deekshabhardwaj@systematixgroup.in
Devanshi Kamdar	IT & ITES	+91-22-6704 8098	devanshikamdar@systematixgroup.in
Hinal Kothari	Metals & Mining	+91-22-6704 8076	hinalkothari@systematixgroup.in
Jennisa Popat	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8066	jennisapopat@systematixgroup.in
Kalash Jain	Midcaps	+91-22-6704 8038	kalashjain@systematixgroup.in
Krishna Zaveri	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8023	krishnazaveri@systematixgroup.in
Mahek Shah	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8040	mahekshah@systematixgroup.in
Nirali Chheda	Banking, Insurance	+91-22-6704 8019	niralichheda@systematixgroup.in
Pashmi Chheda	Banking, Insurance	+91-22-6704 8063	pashmichheda@systematixgroup.in
Pravin Mule	NBFCs & Diversified Financials	+91-22-6704 8034	pravinmule@systematixgroup.in
Prathmesh Kamath	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8022	prathmeshkamath@systematixgroup.in
Purvi Mundhra	Macro-Strategy	+91-22-6704 8078	purvimundhra@systematixgroup.in
Rajesh Mudaliar	Consumer Staples & Discretionary	+91-22-6704 8084	rajeshmudaliar@systematixgroup.in
Ronak Dhruv	NBFCs & Diversified Financials	+91-22-6704 8045	ronakdhruv@systematixgroup.in
Rushank Mody	Pharmaceuticals and Healthcare	+91-22-6704 8046	rushankmody@systematixgroup.in
Swati Saboo	Midcaps	+91-22-6704 8043	swatisaboo@systematixgroup.in
Vivek Mane	Pharmaceuticals and Healthcare	+91-22-6704 8046	vivekmane@systematixgroup.in
Yogeeta Rathod	Midcaps	+91-22-6704 8081	yogeetarathod@systematixgroup.in

Equity Sales & Trading

Name		Desk-Phone	E-mail
Vipul Sanghvi	Co Head of Equities & Head of Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Jignesh Desai	Sales	+91-22-6704 8068	jigneshdesai@systematixgroup.in
Sidharth Agrawal	Sales	+91-22-6704 8090	sidharthagrawal@systematixgroup.in
Shreya Chaudhary	Sales	+91-22-6704 8033	shreyachaudhary@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8003	rahul@systematixgroup.in
Chintan Shah	Sales	+91-22-6704 8061	chintanshah@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Karan Damani	Sales Trading	+91-22-6704 8053	karandamani@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8087	vipulchheda@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Rahul Singh	Dealer	+91-22-6704 8054	rahulsingh@systematixgroup.in
Niraj Singh	Dealer	+91-22-6704 8096	nirajsingh@systematixgroup.in

Corporate Access

Mrunal Pawar	Vice President & Head Corporate Access	+91-22-6704 8088	mrunalpawar@systematixgroup.in
Darsha Hiwrale	Associate Corporate Access	+91-22-6704 8083	darshahiwrale@systematixgroup.in

Production

Madhu Narayanan	Editor	+91-22-6704 8071	madhunarayanan@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in

Operations

Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Hiren Patel	Assistant Manager	+91-22-6704 8056	hirenpatel@systematixgroup.in

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Manjith Nair, Pashmi Chheda, Nirali Chheda** hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

I. **ISSUER SPECIFIC REGULATORY DISCLOSURES**, unless specifically mentioned in point no. 9 below:

- The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
- The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
- The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
- The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
- SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
- The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
- The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
- Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

II. **DISCLAIMER**

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917